Focus on developing proteins with bioactivity
Immune checkpoints proteins
Immune checkpoints are regulators that can inhibit or activate our immune system. They play essential roles in maintaining immune tolerance and modulating the duration and strength of immune responses. Cancer cells can exploit inhibitory pathways to evade the attack from immune system, especially antigen-specific T cell responses.
In recent years, FDA has approved a number of therapeutic monoclonal antibody drugs that target on the inhibitory pathway of immune checkpoints, such as OPDIVO, KEYTRUDA, Ipilimumab, etc. Comparing with traditional Chemotherapy, radiation therapy or targeted therapy, the clinical benefits of immune therapy treatment are astonishing. Pharmaceutical companies start to adjust their R&D pipelines and put more resources on immune checkpoint projects.
To help customers accelerate their study on immune checkpoint targets, DIMA BIOTECH developed a series of high-quality recombinant proteins on immune checkpoint targets . All these proteins are manufactured in HEK293 cells. It is very likely that these recombinant proteins will maintain three-dimensional structure close to native proteins and the authentic post-translational modifications specific to human cells.
Part of our product
1. Protein purity evaluation:
2. Ligand-receptor interaction evaluation:
3. Biosimilar antibody interaction evaluation
Rigorous quality testing
Every batch of recombinant proteins are under rigorous quality testing to make sure the protein stability.
1. Stability test 1: Ligand-receptor interaction testing after multiple freeze-thaw cycles
2. Stability test2: Protein integrity analysis after multiple freeze-thaw cycles
Research grade biosimilar antibody promotion:
With DIMA’s biosimilar antibodies for research, you can study the biological effects of therapeutic antibody drugs without large spending on thereutic grade products. We have validated all these research grade biosimilar products with their target proteins.
1. The ELISA binding testing of Cobolimab biosimilar antibody and recombinant TIM3 protein
Recombinant biosimilar antibody products
|Therapeutic Antibody||Antibody Specificity||DIMA catalog#|
Buy recombinant proteins with free biosimilar antibodies, please contact us for the details.
ReferenceBaumeister, Susanne H., et al. “Coinhibitory pathways in immunotherapy for cancer.” Annual Review of immunology 34 (2016): 539-573.